Palisade Bio, Inc. (NASDAQ:PALI) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Palisade Bio, Inc. (NASDAQ:PALI) have been assigned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $10.20.

Several equities analysts have weighed in on the company. Wall Street Zen raised Palisade Bio from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. HC Wainwright assumed coverage on shares of Palisade Bio in a research note on Thursday, March 26th. They issued a “buy” rating and a $7.00 price objective for the company. Weiss Ratings cut shares of Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 9th. Stifel Nicolaus assumed coverage on shares of Palisade Bio in a research note on Wednesday, February 25th. They set a “buy” rating and a $5.00 target price on the stock. Finally, Wolfe Research started coverage on shares of Palisade Bio in a report on Thursday, April 9th. They set an “outperform” rating and a $7.00 target price on the stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of PALI. Cetera Investment Advisers acquired a new position in Palisade Bio during the 4th quarter worth $25,000. Schonfeld Strategic Advisors LLC acquired a new stake in Palisade Bio in the 4th quarter valued at about $26,000. Virtu Financial LLC purchased a new position in shares of Palisade Bio in the 4th quarter valued at about $28,000. CTC Alternative Strategies Ltd. acquired a new position in shares of Palisade Bio during the first quarter worth about $31,000. Finally, Atom Investors LP acquired a new position in shares of Palisade Bio during the fourth quarter worth about $33,000. 11.79% of the stock is currently owned by hedge funds and other institutional investors.

Palisade Bio Stock Down 1.0%

PALI opened at $1.92 on Thursday. Palisade Bio has a 52 week low of $0.53 and a 52 week high of $2.86. The business has a fifty day simple moving average of $1.97 and a 200-day simple moving average of $1.91. The firm has a market cap of $333.27 million, a P/E ratio of -1.90 and a beta of 1.52.

Palisade Bio (NASDAQ:PALI) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Sell-side analysts expect that Palisade Bio will post -0.21 earnings per share for the current year.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical?stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll?like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.